Clinical Trial of CK-2127107 in Patients with Spinal Muscular Atrophy

By Cure SMA | Published On August 4, 2016

CK-2127107 is a novel fast skeletal muscle troponin activator being developed as a potential treatment for people living with SMA and certain other debilitating neuromuscular and non-neuromuscular conditions associated with muscle weakness and/or muscle fatigue. CK 2127107 is liquid form taken twice a day by mouth.

This first clinical trial of this investigational drug in patients with spinal muscular atrophy (SMA) is a Phase 2, double-blind, randomized, placebo-controlled, multiple dose study of the investigational agent, CK-2127107, in patients with SMA, Types II, III, or IV, ages 12 and older. It is designed to assess the effect of 8 weeks of dosing of CK-2127107 on measures of muscle function and fatigue in both ambulatory and non-ambulatory patients with SMA. The plasma concentration of CK-2127107 will be measured at selected time points and the plasma concentrations obtained may be used to understand the response to different concentrations. The clinical trial is sponsored by Cytokinetics, a biopharmaceutical company in South San Francisco, California, in collaboration with its partner Astellas, a pharmaceutical company in Tokyo, Japan.

In this clinical trial, eligible patients with SMA will randomly be assigned to receive either CK-2127107 or placebo, and neither the participant nor the site Investigator will know which study treatment the patient is receiving. The primary objective of the study is to evaluate measures of skeletal and respiratory muscle function. In addition, safety, tolerability and levels of CK-2127107 will be monitored.

More information about this clinical trial can be found at www.clinicaltrials.org using the following link: https://clinicaltrials.gov/ct2/show/NCT02644668. The clinicaltrials.gov identifier is NCT02644668.

The following sites are currently recruiting patients. As additional sites are added this list will be updated on www.clinicaltrials.gov:

United States, California

Pediatric Neuromuscular Clinic Stanford University
Palo Alto, California, United States, 94304
Contact: Angelica Martinez, (650) 725-4341, ammarti1@stanford.edu

United States, Kansas

University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Contact: Ayla McCalley, (913) 945-9937, amccalley2@kumc.edu

United States, Maryland

Johns Hopkins Hospital Institute for Clinical and Translational Research Pediatric Clinical Research Unit
Baltimore, Maryland, United States, 21287
Contact: Anges Kind Rennie, (443) 287-6294

United States, Massachusetts

Boston Children's Hospital
Boston, Massachusetts, United States, 02115
Contact: Heather M. Fournier, (617) 355-2752 heather.szelag@childrens.harvard.edu

United States, Missouri

Washington University School of Medicine
St. Louis, Missouri, United States, 63110
Contact: Traci Christenson, christensont@neuro.wustl.edu

United States, Ohio

The Ohio State University Wexner Medical Center
Columbus, Ohio, United States, 43210
Contact: Louisa Mezache, (614) 685-3030, louisa.mezache@osumc.edu

United States, Utah

The University of Utah, Clinical Neurosciences Center
Salt Lake City, Utah, United States, 84132
Contact: Andy Rivera, (801) 581-5522, andyr@genetics.utah.edu

Topics: Research, Front Page News

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software